← All trials
NCT04843761
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 20, 2021
- Primary completion
- Oct 31, 2022
- Completion date
- Apr 30, 2023
- First posted
- Apr 14, 2021
- Last posted
- Nov 9, 2021
- Enrollment
- 640
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- Department of Veteran AffairsCollaborator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- University of New South WalesCollaborator
- Gilead SciencesCollaborator
- University of CopenhagenCollaborator
- Medical Research CouncilCollaborator
- AIDS Clinical Trials GroupCollaborator
- Department of Veteran AffairsCollaborator
- NeuroRx, Inc.Collaborator
- University of MinnesotaStudy chair
- International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)Collaborator
- Cardiothoracic Surgical Trials NetworkCollaborator
- Prevention and Early Treatment of Acute Lung Injury (PETAL)Collaborator
- University of UtahOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.